| Element List | Current Year | Previous Year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 3,222.58 | 2,879.37 | 11.92 | ||
| Gross Profit (Loss) | 1,361.48 | 1,236.68 | 10.09 | ||
| Operational Profit (Loss) | 880.28 | 724.27 | 21.54 | ||
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 822.04 | 645.76 | 27.3 | ||
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 809.67 | 641.28 | 26.26 | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 3,778 | 3,568.34 | 5.88 | ||
| Profit (Loss) per Share | 4.11 | 3.23 | |||
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year | Revenues increased by 11.9% to reach 3,223 million Saudi riyals, compared to 2,879 million Saudi riyals for the year 2024 due to: 1- Increase in patients visits and occupancy rates in Inpatient departments. 2- Continued performance improvement of new Subspecialities. 3- Continuous enhancement of operating efficiency of the available resources. |
| The reason of the increase (decrease) in the net profit during the current year compared to the last year is | The company's net profit increased by 27.3%, reaching SAR 822 million compared with SAR 645.8 million for the year 2024, which led to an increase in earnings per share to reach SAR 4.11 compared with SAR 3.23 in 2024. This increase was attributable to: 1- Revenue growth, particularly from inpatient services. 2- Reduction in provisions of expected credit loss, in addition to the collection of a significant portion of outstanding balances from previous years. 3- Lower finance costs, driven by the reduction in outstanding loan balances due to scheduled repayments during the year. 4- The Company’s ability to absorb the pre-operating costs of Yanbu Hospital, which commenced operations in February,01 2026. These costs had an impact on the gross profit margin, which reached 42.25% in FY2025 compared with 42.95% in FY2024. |
| Statement of the type of external auditor's report | Unmodified opinion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | - |
| Reclassification of Comparison Items | Certain comparative figures have been reclassified to comply with the current period presentation of the consolidated financial statements. |
| Additional Information | - The company would like to indicate the possibility of sending investors and financial analysts’ inquiries via email (Shares@mouwasat.com) within 6 working days from the date of publishing the financial statements. |
